Core Viewpoint - The company has successfully raised a total of RMB 106,987.99 million through its public offering, with a net amount of RMB 106,987.99 million after deducting issuance costs, and has established a structured management system for the use of these funds [1][3]. Fundraising Overview - The company issued 70.6 million shares at a price of RMB 16.51 per share, resulting in total fundraising of RMB 116,560.60 million [1]. - After deducting issuance costs of RMB 9,572.61 million, the actual net amount raised was RMB 106,987.99 million [1]. Fund Management - The company has implemented a dedicated fund management system in compliance with relevant laws and regulations, ensuring the protection of investor rights [1]. - A tripartite supervision agreement for fund storage was signed with several banks to regulate the management and use of the raised funds [1]. Fund Usage Status - As of June 30, 2025, the company has invested a total of RMB 476,090,539.82 in fundraising projects [3]. - The remaining balance of the raised funds is RMB 643,049,108.16, with RMB 479,049,108.16 stored in dedicated bank accounts and RMB 164,000,000.00 invested in bank financial products [3]. Specific Project Investments - The company has allocated funds to various projects, including RMB 23,706,690.90 for the development of electrophysiological intervention medical devices and RMB 27,694,669.79 for the marketing service system [3]. - The company has not engaged in any prior investment or replacement of raised funds during the reporting period [3]. Changes in Fund Usage - The company has approved changes and delays in certain fundraising investment projects to enhance the effectiveness of fund usage based on operational needs [3][6]. - The company has also utilized part of the raised funds to provide interest-free loans to its wholly-owned subsidiary for project implementation [3][6].

Core Viewpoint - The report provides a reasonable assurance conclusion regarding the use and storage of funds raised by Shanghai MicroPort EP Medical Technology Co., Ltd. for the year 2024, confirming compliance with relevant regulations and accurate reflection of the financial situation [2][4][5]. Fundraising Overview - The company raised a total of RMB 1,069,879,920.88 through the issuance of 70.6 million shares at a price of RMB 16.51 per share, with the funds verified by DaHua Accounting Firm [4][6]. - As of December 31, 2024, the total amount used from the raised funds was RMB 109,297,928.23, leaving a balance of RMB 687,376,885.41, which includes RMB 662,000,000.00 in bank wealth management products [4][8]. Fund Management - The company has established a management system for the raised funds, ensuring they are stored in dedicated accounts and used strictly for designated projects, with regular audits conducted by the sponsor [5][6]. - The company signed tripartite and quadripartite agreements with banks to ensure proper oversight of the funds, which have been effectively implemented [5][6]. Fund Usage - The funds were allocated to various projects, including RMB 44,175,632.76 for the electrophysiological intervention medical device R&D project, RMB 1,407,722.00 for production base construction, and RMB 63,714,573.47 for marketing service system construction [4][8]. - The company has not used idle funds for temporary working capital or other non-designated projects during the year [6][12]. Project Adjustments - The company has made adjustments to its investment projects, including extending the timeline for the electrophysiological intervention medical device R&D project to December 2027 due to the addition of new sub-projects [14][17]. - The production base construction project has been optimized to reduce costs, with the total investment adjusted from RMB 29,949.49 million to RMB 7,578.92 million [15][17]. - The marketing service system project has seen an increase in investment from RMB 14,376.84 million to RMB 17,522.51 million to enhance market penetration and service capabilities [18][19].